ALIOF Actelion Ltd featured news, full reports, and detailed charts
Actelion Ltd (ALIOF/ALIOF.PK) Wrap Up:
Actelion Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of low molecular weight drugs for various medical needs. Its principal products include Tracleer, an orally available dual endothelin receptor antagonist, approved as a therapy for pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart; and Zavesca, in-licensed from Oxford GlycoSciences, an oral medication indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. The company also offers Ventavis, an inhaled synthetic analogue of prostacyclin that produces potent pulmonary vasodilation and inhibits platelet aggregation. In addition, Actelion evaluates various compounds in various phases of clinical development for treating cardiovascular, cardiopulmonary, immunological, and infectious diseases, as well as metabolic and central nervous system disorders. In addition, it has an exclusive worldwide alliance with Merck & Co, Inc. to discover, develop, and market new classes of renin inhibitors for patients suffering from cardio-renal diseases. Actelion markets Tracleer in the United States, the European Union, Japan, Canada, Australia, and Switzerland. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.Actelion Ltd (ALIOF:Pink OTC Markets Inc)
Snapshot of Actelion Ltd (ALIOF)
|
OPEN
$58.00
|
PREVIOUS CLOSE
$58.00
|
|
|
DAY HIGH
$58.00
|
DAY LOW
$58.00
|
|
|
52 WEEK HIGH
10/14/09 - $63.55
|
52 WEEK LOW
04/17/09 - $41.50
|
|
|
MARKET CAP
6.9B
|
AVERAGE VOLUME 3 mo
312.0
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
119.4M
|
|
|
ALIOF Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
ALIOF Top Compensated Officers
Executives, Board Directors
Key developments for Actelion Ltd (ALIOF)
Actelion Ltd. reported earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net income of CHF 108,462,000 or CHF 0.88 per diluted share on net revenue of CHF 447,302,000. Operating income of CHF 120,368,000 and cash EBIT CHF 157,161,000. For the nine months, the company reported net income of CHF 326,902,000 or CHF 2.66 per diluted share on net revenue of CHF 1,302,541,000 compared to net income of CHF 227,369,000 or CHF 1.84 per diluted share on net revenue of CHF 1,069,620,000 for the same period a year ago. Operating income of CHF 363,244,000 compared to CHF 275,196,000 for the same period a year ago. Cash EBIT of CHF 462,008,000 compared to CHF 355,643,000 for the same period a year ago. Adjusted diluted earnings per share were CHF 3.48, compared to CHF 2.53 during the same period last year. Net cash flow from operations of CHF 300.9 million compared to CHF 410.7 million for the same period a year ago. The company upgraded guidance for fiscal 2009 of both top-line and Cash EBIT growth between 16% and 19% in local currencies. The guidance were towards the upper end of the ranges given. The company's outlook for 2010 continues to be positive. Top-line growth next year will be in the low-double digit range in local currencies, with commercial leverage allowing for both, continued strong cash operating margins and above average investment in innovative growth opportunities.
Actelion Ltd., Q2 2010 Earnings Call, Jul 22 2010
Actelion Ltd. has distributed updated information to Healthcare Professionals who treat type 1 Gaucher patients in the United States regarding the potential use of Zavesca(R) (miglustat) to minimize the impact of the supply shortage of imiglucerase (produced and marketed by Genzyme Corporation under the brand name Cerezyme(R)). Despite strict supply conservation measures currently being implemented, some patients are facing the prospect of an interruption of their imiglucerase treatment. This shortage is now expected to last longer and to affect more patients than initially predicted in June 2009 by the product manufacturer. Accordingly, Actelion has taken all the necessary steps to ensure access to Zavesca(R) where this important oral therapy has been approved for use by patients with Type 1 Gaucher disease, as determined by their physicians.
ALIOF Competitors
| Company | Last | Change |
| Amicus Therapeutics Inc | $3.83 USD | -0.15 |
| BioMarin Pharmaceutical Inc | $16.97 USD | -0.37 |
| EPIX Pharmaceuticals Inc | $0.01 USD | -0.0011 |
| Genzyme Corp | $50.05 USD | +0.42 |
| United Therapeutics Corp | $44.91 USD | +0.10 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | ALIOF | Industry Range |
| Price/Earnings | 17.4x |
|
| Price/Sales | 4.2x |
|
| Price/Book | 5.0x |
|
| Price/Cash Flow | 16.9x |
|
| TEV/Sales | 3.5x |
|
|
ALIOF |
||
ALIOF transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Actelion Ltd
More news for ALIOF
Actelion updates US Healthcare Professionals for patients with type 1 Gaucher disease - Information on the potential use of Zavesca(R) (miglustat) oral capsule to address the supply shortage of intravenous enzyme replacement therapy (imiglu
ALLSCHWIL, SWITZERLAND--(Marketwire - 09/08/09) - ALLSCHWIL/BASEL, SWITZERLAND - 8 September 2009 - Actelion Ltd (SIX: ATLN) has distributed updated information to Healthcare Professionals who treat type 1 Gaucher patients in the United States regarding the potential use of Zavesca� (miglustat) to minimize the impact of the supply shortage of imiglucerase (produced and marketed by Genzyme Corporation under the brand name Cerezyme�).Despite strict supply conservation measures currently being implemented, some patients are facing the prospect of an interruption of their imiglucerase treatment. This shortage is now expected to last longer and to affect more patients than initially predicted in June 2009 by the product manufacturer.Accordingly, Actelion has taken all the necessary steps to ensure access to Zavesca� where this important oral therapy has been approved for use by patients with Type 1 Gaucher disease, as determined by their physicians. In the United States, Zavesca� has been available since 2003.Following communication with the US Food and Drug Administration (FDA), Actelion has issued the following letter to remind Health Care Professionals in the United States about the availability of Zavesca� as an immediate treatment option for appropriate type 1 Gaucher patients in relation to the current imiglucerase shortage. Health Care Professionals may also receive additional information by email (usmedinfo@actelion.com) or by calling toll-free (866) 228-3546.###Notes to the editor:About Zavesca�Zavesca� (100 mg miglustat capsule) is indicated for t...Click here to read the whole Article (external link)